The two abstracts compare U.S. neurologists’ self-reported perceptions with actual prescribing behavior to assess if the use of highly effective therapies as first-line treatment is increasing over time and what disease metrics and treatment expectations drive the selection of monoclonal antibody agents in patients recently switched to a new therapy
EXTON, Pa., Aug. 7, 2018 /PRNewswire/ — Spherix Global Insights, an independent business intelligence and market research company, today announced that two abstracts based upon real world data collected as part of their multiple sclerosis (MS) patient chart audits have been accepted for presentation at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which will take place in Berlin, Germany from October 10-12, 2018. The RealWorld Dynamix™ audits include a short survey assessing neurologists’ self-reported prescribing behaviors and perceptions and a database with over 1,000 patient charts entered by the collaborating neurologists. This unique methodology allows for comparison of neurologists’ self-reported behavior with actual patient-level treatment decisions to reveal potential areas of disconnect, as well as subgroup analyses based upon prescribers’ demographic characteristics.
The posters will be presented by lead author Robert Naismith, M.D., Director, John L. Trotter MS Clinic at Washington University, Saint Louis, MO. “Although an aggressive first-line therapy approach and the evolving treatment paradigm for patients with progressive forms of MS have been of increased focus at recent conferences, the frequency of high-efficacy therapy use among these patient types has not been formally assessed,” said Dr. Naismith, who advises Spherix on multiple sclerosis-related intelligence and insights. “The Spherix annual audits provide robust real-world databases allowing for trending of practice paradigm shifts and assessing the impact of new products, such as ocrelizumab with its first-in market primary progressive MS indication, on therapy selection during highly dynamic points in the patient journey.”
The Spherix-sponsored data to be presented includes:
[P868] Treatment Optimization: Are U.S. Neurologists Using High-Efficacy Therapies for Newly Diagnosed RRMS? (Poster Session 2, October 11, 2018, 5:15-7:15 p.m. CET)
[P1212] Switching Treatments in Progressive MS: How are U.S. Neurologists Approaching Disease-Modifying Treatment over Time? (Poster Session 3, October 12, 2018, 12:15-2:15 p.m. CET)
The complete abstracts will publish on September 26, 2018.
About RealWorld Dynamix Audits
RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis (US) and RealWorld Dynamix™: DMT Switching in Multiple Sclerosis (US) blend attitudinal and demographic physician survey data with patient record data to uncover how practice type and setting and certain beliefs influence the treatment pathway and to understand how marketed DMTs are being used by physicians and for what patient types. The audits augment claims data by providing the “why” behind the new start and switching behavior and by providing essential details not available in claims data that may be driving the therapy selection, such as MS subtype, payer pressure, co-morbid conditions, or patient requests. The report also captures physician’s perspectives about products in development and the impact they will have on the current treatment paradigm among new start or switch patients.
The current RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis (US) is the second annual audit and the RealWorld Dynamix™: DMT Switching in Multiple Sclerosis (US) is the third annual audit allowing for tracking how market events, such as new product launches, product withdrawals, generic entry, and new guidelines, are evolving the market. An audit focused on the progressive forms of MS, RealWorld Dynamix™: Progressive Forms of Multiple Sclerosis (US), will publish in November 2018.
About Spherix Global Insights
Spherix Global Insights is an independent business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
To view media coverage of this release, click here.